STOCKS TELEGRAPH

Tag: INBS stock

  • Intelligent Bio (INBS) Stock Rallies On Strong Financial Performance

    Intelligent Bio (INBS) Stock Rallies On Strong Financial Performance

    Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares are seeing a significant increase today, rising 66.14% to $2.63, after the company released encouraging financial data. For the fiscal year that concluded on June 30, 2024, the firm released preliminary unaudited sales figures of $0.73 million and $3.11 million, respectively. Furthermore, in comparison to the previous year, INBS expects a 20% increase in cartridge sales and a 26% increase in reader sales for the fiscal year.

    Drivers of Revenue Expansion

    Intelligent Bio Solutions credits a number of critical variables, such as growing market demand, elevated brand and product awareness, and client base development, for this remarkable revenue growth.

    The firm has significantly increased its reader install base, which currently exceeds 1,000 devices, as a result of its targeted efforts to provide new solutions across safety-critical industries where drug use presents considerable concerns. Because each reader needs a constant supply of cartridges to function, the company’s continued expansion is supported by a consistent source of recurring income.

    Strategic Focus on Safety-Critical Sectors

    Intelligent Bio Solutions has deliberately focused on sectors where dependable and non-invasive drug testing solutions are critical, including manufacturing, transportation, construction, and logistics. Through strategic alliances, the firm has expanded its reach into new areas and strengthened its position in these industries by meeting these crucial needs.

    With over 400 active customer accounts and growing, INBS demonstrates its product’s strong market resonance and its ability to meet the testing needs of safety-critical industries.

    Progress in Clinical Studies and Regulatory Milestones

    In addition to its financial successes, Intelligent Bio Solutions has made significant strides in its clinical study plan required for the FDA 510(k) submission. The company recently announced a partnership with CenExel to conduct a method comparison study as part of this plan.

    Having completed approximately one-third of the subject enrollment targets and the in-clinic portion of a pharmacokinetic (PK) study on opiates in human fingerprint sweat, Intelligent Bio (INBS) is currently analyzing the collected specimens and data, marking a crucial step forward in its regulatory journey.

  • Pre-Market Movers: A Comprehensive Analysis of Intelligent Bio Solutions Inc.’s Recent Stock Activity

    Pre-Market Movers: A Comprehensive Analysis of Intelligent Bio Solutions Inc.’s Recent Stock Activity

    In the recent financial news, Intelligent Bio Solutions Inc. (INBS), a leading medical technology firm, has demonstrated a robust pre-market performance. This article delves into the company’s stock’s recent activity, shedding light on various aspects of its financial standing.

    Intelligent Bio Solutions: An Overview

    Intelligent Bio Solutions Inc. is a trailblazer in the field of medical technology. With its proprietary Intelligent Fingerprinting Drug Screening System, the company has transformed the landscape of non-invasive, rapid testing solutions.

    The system’s versatility has seen it being adopted by a diverse range of industries, contributing to a steady rise in the company’s revenue.

    Recent Financial Performance

    This firm of the US stocks market has recently unveiled its financial outcomes for the initial fiscal quarter concluding on September 30, 2023.

    It disclosed a substantial year-over-year surge in revenue and government support income, underscoring the effective implementation of its expansion strategies and robust organic growth.

    Revenue Growth

    The company’s combined revenue and government support income rose by 191% to $0.91 million for the first fiscal quarter. This spike is attributed to the launch of its Intelligent Fingerprinting Drug Screening System in the Asia-Pacific region and the acquisition of Intelligent Fingerprinting Ltd in October 2022.

    Net Loss

    The net loss attributable to INBS for the first fiscal quarter was $2.4 million. This increase primarily resulted from the combined results of operations after the acquisition of IFP.

    Cash Flow

    The company ended the quarter with cash and cash equivalents of approximately $0.2 million. However, it managed to raise approximately $4.378 million, prior to deducting underwriting discounts and commissions and offering expenses, via a registered underwritten public offering of the Company’s securities.

    Plans and Milestones

    In its strategic pursuit of growth, INBS has made significant strides in expanding its market presence. The company has successfully entered new markets, including South America, and has continued to grow organically in its existing markets.

    Expansion and Growth

    The firm has made significant progress in its initiatives to extend into the U.S. market. Alongside the creation of novel assays for ketamine and tramadol, INBS has acquired eight fresh clients in Australia, spanning diverse sectors such as mining, aviation, construction, manufacturing, and agriculture.

    Pre-Market Performance

    INBS has showcased an impressive pre-market performance recently, indicating heightened early investor interest. The stock price reflected a significant change of +92.51%, accompanied by a substantial pre-market volume of 220.987 million shares.

    The company’s pre-market change stood at +23.57%, closing at 0.5400 USD. This considerable increase amounted to a pre-market change of 0.1030. The pre-market gap percentage stood at +13.89%, suggesting positive momentum.

    Market Capitalization

    Currently, Intelligent Bio Solutions Inc. holds a market capitalization of 3.817 million USD. Despite experiencing an -84.45% decline over the past year, the company’s recent pre-market performance paints a promising picture for the future.

    Conclusion

    With its strong pre-market performance, Intelligent Bio Solutions Inc. (INBS) has emerged as a key player among pre-market movers. The stock’s recent activity is a testament to the company’s growth strategy, innovative solutions, and successful market expansion. As INBS continues to advance in its field, investors are likely to keep a keen eye on its journey.